| HTA implementation roadmap in Central and Eastern European countries Z Kaló, A Gheorghe, M Huic, M Csanádi, FB Kristensen Health economics 25, 179-192, 2016 | 98 | 2016 |
| Is there a reason for concern or is it just hype?–A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars A Inotai, CPJ Prins, M Csanadi, D Vitezic, C Codreanu, Z Kalo Expert opinion on biological therapy 17 (8), 915-926, 2017 | 66 | 2017 |
| All‐cause mortality versus cancer‐specific mortality as outcome in cancer screening trials: A review and modeling study EAM Heijnsdijk, M Csanádi, A Gini, K Ten Haaf, R Bendes, A Anttila, ... Cancer medicine 8 (13), 6127-6138, 2019 | 41 | 2019 |
| Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts A Inotai, M Csanadi, G Petrova, M Dimitrova, T Bochenek, T Tesar, K York, ... BioMed research international 2018, 2018 | 41 | 2018 |
| HTA implementation in Latin American countries: comparison of current and preferred status D Rosselli, C Quirland-Lazo, M Csanádi, EMR de Castilla, NC González, ... Value in health regional issues 14, 20-27, 2017 | 39 | 2017 |
| Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015 P Ozieranski, M Csanadi, E Rickard, J Tchilingirian, S Mulinari JAMA network open 2 (6), e196253-e196253, 2019 | 37 | 2019 |
| When health technology assessment is confidential and experts have no power: the case of Hungary M Csanádi, O Löblová, P Ozierański, A Harsányi, Z Kaló, M McKee, ... Health Economics, Policy and Law 14 (2), 162-181, 2019 | 31 | 2019 |
| Benefits Of Timely Care In Pancreatic Cancer: A Systematic Review To Navigate Through The Contradictory Evidence G Lukács, Á Kovács, M Csanádi, M Moizs, I Repa, Z Kaló, Z Vokó, ... Cancer Management and Research 11, 9849, 2019 | 28 | 2019 |
| The emerging social science literature on health technology assessment: a narrative review O Löblová, T Trayanov, M Csanádi, P Ozierański Value in Health 23 (1), 3-9, 2020 | 26 | 2020 |
| The influence of health systems on breast, cervical and colorectal cancer screening: an overview of systematic reviews using health systems and implementation research frameworks J Priaulx, E Turnbull, E Heijnsdijk, M Csanádi, C Senore, HJ de Koning, ... Journal of health services research & policy 25 (1), 49-58, 2020 | 25 | 2020 |
| A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease M Csanadi, T Agh, A Tordai, T Webb, D Jeyakumaran, N Sengupta, ... Expert review of hematology 12 (5), 311-323, 2019 | 24 | 2019 |
| The implications of external price referencing on pharmaceutical list prices in Europe M Csanádi, Z Kaló, CPJ Prins, E Grélinger, AM Kiss, FU Fricke, L Fuksa, ... Health Policy and Technology 7 (3), 243-250, 2018 | 24 | 2018 |
| Policy practices to maximise social benefit from biosimilars A Inotai, M Csanádi, D Vitezic, I Francetic, T Tesar, T Bochenek, ... J Bioequivalence Bioavailability 9 (4), 467-472, 2017 | 24 | 2017 |
| Health Technology Assessment Implementation in Ukraine: Current Status and Future Perspectives M Csanádi, A Inotai, O Oleshchuk, O Lebega, B Alexandra, O Piniazhko, ... International Journal of Technology Assessment in Health Care, 1-8, 2019 | 20 | 2019 |
| Implementation of palliative care consult Service in Hungary–integration barriers and facilitators AT Zemplényi, Á Csikós, M Csanádi, M Rutten-van Mölken, C Hernandez, ... BMC Palliative Care 19 (1), 1-12, 2020 | 19 | 2020 |
| Drug policy in Hungary A Inotai, M Csanádi, A Harsányi, B Németh Value in health regional issues 13, 16-22, 2017 | 19 | 2017 |
| Overview on the current implementation of health technology assessment in the healthcare system in Hungary B Németh, M Csanádi, Z Kaló International journal of technology assessment in health care 33 (3), 333-338, 2017 | 19 | 2017 |
| Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a … JG Pitter, M Csanádi, A Szigeti, G Lukács, Á Kovács, M Moizs, I Repa, ... BMC health services research 19 (1), 1-13, 2019 | 18 | 2019 |
| Influence of biosimilar infliximab launch on the utilization pattern of biological medicines: the case of Hungary A Harsányi, M Csanádi, K Márky, ÁZ Vincziczki, Z Kaló, A Inotai Expert review of pharmacoeconomics & outcomes research 20 (6), 653-659, 2020 | 17 | 2020 |
| Cost assessment of inpatient care episodes of stroke in Romania L Lorenzovici, A Szekely, M Csanádi, P Gaál Frontiers in Public Health 8, 869, 2020 | 17 | 2020 |
Zoltán KalóCenter for Health Technology Assessment, Semmelweis University; Syreon Res在 semmelweis.hu 的电子邮件经过验证
